It requires virus infected patients, like her, to inhale the drug via a nebuliser to bring it deep into the lungs. The trial, which used interferon beta, showed that patients who were given Synairgen's formulation had a 79 percent lower risk of developing severe forms of the disease compared to placebo. Patients who received the drug, SNG001, were more than twice as likely to recover from the virus infection as those on placebo, the company said. Shares of the company nearly tripled to 97.50 pence, up from a Friday close of 36.50 pence. The measure of breathlessness was also markedly reduced in patients who received the drug, Synairgen added.

Source: The Standard July 20, 2020 08:15 UTC